Panacea Biotec Wins Income Tax Case: Rs. 9.16 Cr Demand Cancelled:

Panacea Biotec Limited informed stock exchanges like National Stock Exchange of India and BSE Limited about an important update in its tax case for the financial year 2019–20 (Assessment Year 2020–21).

Also Read

CBIC Update on SEZ Goods: Re-export from DTA Now Eligible for Drawback

Earlier, the tax department had asked the company to pay about Rs. 9,16,00,000 (Rs. 9.16 crore). This demand arose because the tax officer did not allow expenses of around Rs. 3,44,00,000 (Rs. 3.44 crore) under Section 14A of the Income Tax Act, which relates to expenses linked with tax-free income. However, on April 29, 2026, the Income Tax Appellate Tribunal (ITAT) gave its decision in favor of the company It cancelled the earlier order of the Commissioner of Income Tax (Appeals) and removed both the disallowed expenses and the tax demand. This means the company no longer has to pay Rs. 9,16,00,000, which is a positive outcome for its finances. The company shared this update publicly as required under SEBI rules to keep investors informed.